FDA Alert

FDA Approves First Generic Fluticasone Propionate Inhalation Aerosol for Asthma Maintenance Therapy in Patients Aged 4 Years and Older

Edited by:
Anthony Calabro, MA

Key Highlights

  • FDA approved the first generic of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 mcg per actuation.
  • The generic is indicated for maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older.
  • Prescribing information mirrors brand-label contraindications, warnings, and precautions.
  • Approval aims to increase access and affordability of inhaled corticosteroid therapy.

On March 3, 2026, the FDA approved the first generic of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 mcg per actuation, for the maintenance treatment of asthma as prophylactic therapy in adults and children aged 4 years and older. Fluticasone propionate is an inhaled corticosteroid designed to reduce airway inflammation and prevent asthma symptoms, including wheezing and shortness of breath.

According to the FDA, the approval represents the first generic metered-dose inhaler form of fluticasone propionate inhalation aerosol.

“Today's approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment,” Iilun Murphy, MD, Director of the Office of Generic Drugs in the FDA's Center for Drug Evaluation and Research, said in a press release. “Generic medications provide patients with safe, effective, and more affordable treatment options.”

The prescribing information for fluticasone propionate includes the same contraindications, warnings, and precautions as Flovent HFA. The drug should not be used as primary treatment in status asthmaticus or other acute asthma episodes requiring intensive measures, or in patients with hypersensitivity to any component. Warnings include oropharyngeal candidiasis and immunosuppression. Clinicians are advised to consult the full prescribing information for a comprehensive description of adverse reactions and precautions.

The approved dosage strength is 44 mcg per actuation and is indicated for ongoing maintenance therapy in patients aged 4 years and older. Clinicians should contact the manufacturer for information regarding product availability.

Reference

U.S. Food and Drug Administration. FDA approves first generic Flovent HFA for treatment of asthma. FDA. Published March 3, 2026. Accessed March 3, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-generic-flovent-hfa-treatment-asthma